2023
DOI: 10.1016/j.ymthe.2022.09.004
|View full text |Cite
|
Sign up to set email alerts
|

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
13
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 9 publications
(14 citation statements)
references
References 94 publications
1
13
0
Order By: Relevance
“…We have recently demonstrated that the inhibition of SGPL1 by THI restored myelin organization in the corpus callosum of R6/2 mice [ 18 ]. In order to verify whether the compound might exert similar effect in the striatum, we performed ultrastructural analyses in HD and control mice.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…We have recently demonstrated that the inhibition of SGPL1 by THI restored myelin organization in the corpus callosum of R6/2 mice [ 18 ]. In order to verify whether the compound might exert similar effect in the striatum, we performed ultrastructural analyses in HD and control mice.…”
Section: Resultsmentioning
confidence: 99%
“…Recently, we have demonstrated that the administration of THI, a specific inhibitor of S1P lyase (SGPL-1), results therapeutically effective in R6/2 mice by evoking neuroprotective pathways, reducing mHtt aggregates and preserving white matter integrity in the corpus callosum [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations